ClinicalTrials.Veeva

Menu
A

Adams Clinical | Watertown, MA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

LY3002813
Donanemab
Pimavanserin
serotonin
Esketamine
Rapastinel
BHV-7000
norepinephrine
Troriluzole
Seltorexant

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

11 of 26 total trials

A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)

This study will investigate different donanemab dosing regimens and their effect on the frequency and severity of ARIA-E in adults with early symptom...

Active, not recruiting
Alzheimer's Disease
Mental Disorders
Drug: Placebo
Drug: Donanemab

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.Additional part...

Active, not recruiting
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

The purpose of this study is to assess the safety, tolerability and effect of study drug LY3372689 in participants with early symptomatic Alzheimer's...

Active, not recruiting
Alzheimer Disease
Drug: LY3372689
Drug: Placebo

The reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early Alzheimer's d...

Active, not recruiting
Alzheimer's Disease
Drug: Remternetug (SC)
Drug: Placebo

This study is open to adults between 18 and 65 with a type of depression (major depressive disorder) for whom previous treatments for depression did...

Enrolling
Depressive Disorder, Major
Drug: BI 1569912
Drug: Placebo

This study is designed to evaluate safety and efficacy of fosgonimeton (ATH-1017) in the treatment of mild to moderate Alzheimer's disease with a ran...

Active, not recruiting
Alzheimer Disease
Dementia of Alzheimer Type
Drug: Placebo
Drug: ATH-1017

The study's purpose its to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compu...

Enrolling
Obsessive-Compulsive Disorder
Drug: Troriluzole
Drug: Placebo

The purpose of this study is to determine the efficacy and safety of BHV-7000 in participants with Major Depressive Disorder (MDD)

Enrolling
Major Depressive Disorder
Drug: BHV-7000
Drug: Placebo

The purpose of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with obsessive compuls...

Invitation-only
Obsessive Compulsive Disorder
Drug: Troriluzole (BHV-4157)

The purpose of this study is to evaluate the long-term safety and tolerability of BHV-7000, in participants with Major Depressive Disorder (MDD).

Invitation-only
Major Depressive Disorder
Drug: BHV-7000

Alzheimer's disease (AD) is a progressive, irreversible neurological disorder and is the most common cause of dementia in the elderly population. Cli...

Active, not recruiting
Alzheimer's Disease (AD)
Drug: Placebo for ABBV-552
Drug: ABBV-552

Trial sponsors

Lilly logo
A
Janssen (J&J Innovative Medicine) logo
Acadia Pharmaceuticals logo
Allergan logo
Biohaven logo
Biohaven logo
AbbVie logo
Athira Pharma logo
Boehringer Ingelheim logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems